India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has approved a wide range of recombinant DNA (r-DNA)-origin drugs and biologics for manufacture ...
Antibodies are the number one immune cells that fight against infection and diseases. However, beyond their natural usage, biochemistry has devised several ways in which these antibodies can be ...
The first peer-reviewed journal in the field of human gene therapy, providing all-inclusive coverage of the research, methods, and clinical developments that are driving today's explosion of gene ...
The Central Drugs Standard Control Organisation (CDSCO) has granted multiple CT-18 approvals between January 2020 and ...
Twenty-seven entreaties drafted and endorsed following discussions at the 50-year anniversary summit of the 1975 Asilomar Conference on Recombinant DNA have been published and archived at Rice ...
- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of ...
The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...
Despite the hundreds of millions of vials of blood drawn every year for medical testing, scientists have only scratched the surface of its diagnostic potential. The blood proteome — which includes all ...
The AI2Health cluster of the Ken Kennedy Institute and the Synthetic Biology Institute at Rice University hosted a debriefing and collaborative discussion session on the Spirit of Asilomar summit June ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results